Clinical Trial Update: CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial update comparing concurrent chemoradiotherapy with temozolomide versus radiotherapy alone in patients with IDH-wildtype/TERT promoter-mutan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Grade II/III Glioma | EARLY_Phase 1 | Status: UNKNOWN